Tirzepatide is the current heavyweight of the weight-loss drugs. It is sold as Mounjaro for diabetes and Zepbound for obesity, and in head-to-head testing it beat semaglutide. It is also, like semaglutide, a fully approved drug with real trials, so this is another page where the evidence is solid rather than speculative.
Same caution as always. The approved product is what the trials studied. Gray-market “research” tirzepatide is not that product, and since the shortage ended, compounded versions are largely being shut down.
Strong and human. Tirzepatide has a full slate of large randomized trials, the SURPASS program in diabetes and the SURMOUNT program in obesity, plus a dedicated sleep-apnea trial and a cardiovascular outcomes trial. Claims here rest on that, not on animal work.
Tirzepatide is the first drug to hit two gut-hormone receptors at once, GIP and GLP-1. That dual action is the whole idea, and it is why it is described as first-in-class. It is a once-weekly injection built on a modified peptide backbone with a fatty-acid tail that binds albumin to make it last a week. Eli Lilly makes it.
Two brands, one molecule. Mounjaro for type 2 diabetes. Zepbound for obesity and, since late 2024, for obstructive sleep apnea in people with obesity.
Lilly developed it and ran the SURPASS diabetes trials starting in 2018. Mounjaro was approved for diabetes in 2022, Zepbound for weight management in 2023, and in December 2024 Zepbound became the first drug ever approved for obstructive sleep apnea.
The GLP-1 arm does what semaglutide does: glucose-dependent insulin release, lower glucagon, slower stomach emptying, and reduced appetite. The GIP arm adds a second incretin signal that appears to help with insulin sensitivity and appetite, and may even blunt some of the nausea. The theory is that hitting both pathways works better than one, and the head-to-head data back that up.
Approved for diabetes, weight management, and sleep apnea with obesity. Off-label and gray-market use is mostly weight loss.
The side-effect profile mirrors semaglutide. Gastrointestinal issues lead the list, and some people find tirzepatide a bit harder on the gut. It carries the same boxed thyroid C-cell tumor warning and the same contraindication for a personal or family history of medullary thyroid cancer or MEN2. Pancreatitis and gallbladder disease are less common risks.
Two commonly asked-about effects. Some people report hair loss, around 5 to 6% versus 1% on placebo, attributed to rapid weight loss rather than a direct drug effect, and usually temporary. And as with any large weight loss, some of what you lose is muscle, so training and protein help preserve it. Tell your anesthesia team before surgery, since it slows stomach emptying.
Approved labeling, so this is factual. It starts at 2.5 mg weekly for four weeks, which is a starter dose, not a maintenance dose, then steps up by 2.5 mg no more than every four weeks, through 5, 7.5, 10, 12.5, to a maximum of 15 mg. Zepbound maintenance for weight is 5, 10, or 15 mg, and for sleep apnea 10 or 15 mg.
Same gray-market caution as semaglutide. Compounded and “research” tirzepatide is not the approved product, dosing errors are a documented risk, and this site does not give injection instructions.
Fully FDA-approved, including the sleep-apnea use. The compounding window has closed. The FDA declared the tirzepatide shortage resolved in late 2024, the enforcement grace periods ended in 2025, courts upheld the delisting, and routine compounding is being wound down with only narrow clinical-need exceptions.
Against semaglutide, tirzepatide wins on weight in the head-to-head, while semaglutide has the deeper cardiovascular and kidney record. Against retatrutide, the investigational triple agonist, tirzepatide is the approved option you can actually get, while retatrutide’s trial numbers are higher but it is not approved and its long-term safety is not established. A head-to-head of those two is expected around the end of 2026.
Is tirzepatide the same as Mounjaro and Zepbound? Yes. One molecule, two brands for different approved uses.
How is it different from Ozempic? Ozempic is semaglutide, which hits one receptor. Tirzepatide hits two and beat it head-to-head on weight.
How much weight do people lose? About 21% on average at the top dose over 72 weeks in the trial. Individual results vary.
Is compounded tirzepatide the same thing? No. It is not the approved product, and routine compounding is being shut down now that the shortage is over.
What are the main side effects? Nausea, diarrhea, vomiting, and constipation, worst during dose increases.
Do I need to stop before surgery? Tell your anesthesia team. Because it slows stomach emptying, they may take extra precautions.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.